Korea, Republic of
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from AbClon.
AbClon announced on Tuesday that it has signed an exclusive technology transfer agreement with TCT Health Technology, a Turkish company, for its homegrown CAR-T cell therapy, AT101.
The agreement, signed on Feb. 28, will remain valid for 20 years from its effective date. Under the deal, AbClon will transfer CD19 CAR sequences, CD19 CAR-T-specific manufacturing processes and analytical methods, as well as CMC-related technologies. In return, TCT Health Technology will gain exclusive rights to develop and commercialize AT101 in the Turkish market.
This is the News section of the company profile page for AbClon on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
